<DOC>
	<DOCNO>NCT00617617</DOCNO>
	<brief_summary>The purpose research study determine give men early stage ( Grade 1-2 ) prostate cancer dietary supplement soybean call isoflavones , change blood hormone level . Isoflavones substance find high concentration soybean convert intestine hormone-like compound similar estrogen . They also think cancer fight property . Clinical trial suggest isoflavones increase certain sex hormone , result slow production prostate cancer cell . This study determine add isoflavones ( supply Prevastein HC® ) 80 mg/day pill form change risk factor cause early stage prostate cancer progress advance disease .</brief_summary>
	<brief_title>The Specific Role Isoflavones Reducing Prostate Cancer Risk</brief_title>
	<detailed_description>To prevent bias outcome study , double-blind study design , trialists participant blind specific nature product ( isoflavones placebo ) . Participants group discourage increase intake dietary isoflavones form tofu , soy bean , soy milk , etc . In addition , intervention include active counseling dietary modification supplementation one group . Monthly appointment make participant data collection toxicity assessment . Schema : This control , randomize , double blind clinical trial , one experimental one control group ( n - 75/arm ) . Participants experimental group consume isoflavones supplement form Prevastein HC® , deliver 80 mg ( 40 mg/dose ) biologically active isoflavones control group receive identical placebo . The isoflavones supplement placebo tablet manufacture package Cognis Corporation . 1 . Isoflavones supply charge Cognis Corporation , LaGrange , Illinois Prevastein HC® . Each Prevastein HC® tablet delivers 20 mg biologically active isoflavones , available absorption . Participants consume 2 tablet twice daily ( meal ) addition usual diet . 2 . Placebo supply charge Cognis Corporation , LaGrange , Illinois indistinguishable tablet . Participants consume 2 tablet twice daily ( meal ) addition usual diet . 3 . A standardized multivitamin supply charge .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males , age 50 80 Diagnosed grade 12 prostate cancer ( Gleason Score 2 6 ) Note : patient Gleason primary pattern 4 ( 4+1 4+2 ) eligible . No prior current therapy prostate cancer No history cancer except nonmelanoma skin cancer No known history hepatic and/or renal disease No evidence prostatitis urinary tract infection ( men treat antibiotic may enrol 30 day completion therapy give still meet eligibility criterion ) No antibiotic use within 30 day registration Close ideal body weight ( Body Mass Index great 32 Kg/m² ) Omnivorous diet Able willing give write consent Less 50 year 80 year age Prostate cancer beyond grade 2 ( Gleason Score great 6 ) Gleason primary pattern 4 ( 4+1 4+2 ) Prior plan treatment prostate cancer stage Prior history cancer except nonmelanoma skin cancer Current use nutritional supplement , include modular supplement agent antioxidant property e.g . retinoids , betacarotene , isoflavones Allergy study agent Known history hepatic renal disease Body Mass Index great 32 Kg/m² Vegetarian/vegan diet Diet high soy product ( men routinely consume diet high soy product may enrol 30 day eliminate soy product diet ) Prostatitis urinary tract infection Treatment antibiotic within 30 day registration</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>isoflavones</keyword>
	<keyword>soy</keyword>
</DOC>